secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2026-02-13T23:59:59+00:00
Accession:  0001213900-26-015895
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Pharma posts first revenue of $3.9M from LYMPHIR launch; Nasdaq warns of bid price deficiency
--------------------------------------------------------------------------------

- Q1 FY2026 revenue $3.9M from initial LYMPHIR sales; net loss $8.2M ($0.41 loss per share).
- Cash and equivalents $7.7M; raised ~$20.9M from equity financings in quarter.
- Nasdaq notified company of bid price deficiency; has until Aug 10, 2026 to regain compliance.
- LYMPHIR launched Dec 2025; early physician adoption; international patient access via Named Patient Programs.
- Late-stage pipeline includes Mino-Lok and Halo-Lido; engaging with FDA on next steps.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390026015895/0001213900-26-015895-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390026015895/ea0276948-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-015895

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer